Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma
NCT01251107Phase 3Completed
- Sponsor
- Michelangelo Foundation
- Start
- Mar 2000
- Primary completion
- Nov 2009
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bleomycin, etoposide, pegylated liposomal doxorubicin, cyclophosphamide, vincristine sulfate liposome injection and 2 more in Hodgkin lymphoma (HL), sponsored by Michelangelo Foundation. Primary endpoint: Freedom from first progression at 5 years. Started Mar 2000; status: completed.
02
Drugs
bleomycinetoposidepegylated liposomal doxorubicincyclophosphamidevincristine sulfate liposome injection
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01251107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01251107.